SF3B3 and neoplasm: Further functional studies in the context of clear cell renal carcinoma show that knockdown of SF3B3 in SF3B3-overexpressing cells in vivo reduced tumour growth, highlighting the potential utility of SF3b inhibitors as a therapeutic agent for patients with SF3B3 amplification and/or overexpression (Chen et al. 2017).